Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food and Rabeprazole Effect on HMPL-453 PK
NCT05930119Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Mar 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fanregratinib in intrahepatic cholangiocarcinoma (ICC) (4 arms), sponsored by HUTCHMED. Primary endpoints: Area Under the Curve from time zero to last measurable concentration, Area Under the Curve from time zero to infinity and 1 more. Started Mar 2023; status: completed.
02
Drugs
fanregratinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05930119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930119.